Literature DB >> 27057292

Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels.

Adedotun A Ogunsua1, Amir Y Shaikh1, Mohamed Ahmed1, David D McManus1.   

Abstract

Atrial fibrillation (AF) is an increasingly prevalent condition and the most common sustained arrhythmia encountered in ambulatory and hospital practice. Several clinical risk factors for AF include age, sex, valvular heart disease, obesity, sleep apnea, heart failure, and hypertension (HTN). Of all the risk factors, HTN is the most commonly encountered condition in patients with incident AF. Hypertension is associated with a 1.8-fold increase in the risk of developing new-onset AF and a 1.5-fold increase in the risk of progression to permanent AF. Hypertension predisposes to cardiac structural changes that influence the development of AF such as atrial remodeling. The renin angiotensin aldosterone system has been demonstrated to be a common mechanistic link in the pathogenesis of HTN and AF. Importantly, HTN is one of the few modifiable AF risk factors, and guideline-directed management of HTN may reduce the incidence of AF.

Entities:  

Keywords:  ACE inhibitors; RAAS pathway; arrhythmias; benign essential hypertension; nonvalvular atrial fibrillation

Mesh:

Year:  2015        PMID: 27057292      PMCID: PMC4814009          DOI: 10.14797/mdcj-11-4-228

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  59 in total

1.  A comparison of rate control and rhythm control in patients with atrial fibrillation.

Authors:  D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

2.  A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study.

Authors:  Simon Stewart; Carole L Hart; David J Hole; John J V McMurray
Journal:  Am J Med       Date:  2002-10-01       Impact factor: 4.965

3.  Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation.

Authors:  A Goette; T Staack; C Röcken; M Arndt; J C Geller; C Huth; S Ansorge; H U Klein; U Lendeckel
Journal:  J Am Coll Cardiol       Date:  2000-05       Impact factor: 24.094

4.  Analysis of risk factors involved in oral-anticoagulant-related intracranial haemorrhages.

Authors:  J Berwaerts; J Webster
Journal:  QJM       Date:  2000-08

5.  Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Eric P Leip; Philip A Wolf; Ralph B D'Agostino; Joanne M Murabito; William B Kannel; Emelia J Benjamin
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

6.  Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.

Authors:  Emmanuelle Vermes; Jean-Claude Tardif; Martial G Bourassa; Normand Racine; Sylvie Levesque; Michel White; Peter G Guerra; Anique Ducharme
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

7.  Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.

Authors:  Elaine M Hylek; Alan S Go; Yuchiao Chang; Nancy G Jensvold; Lori E Henault; Joe V Selby; Daniel E Singer
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

8.  Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.

Authors:  Philippe L L'Allier; Anique Ducharme; Pierre-Frédéric Keller; Holly Yu; Marie-Claude Guertin; Jean-Claude Tardif
Journal:  J Am Coll Cardiol       Date:  2004-07-07       Impact factor: 24.094

9.  Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways.

Authors:  Sophie Cardin; Danshi Li; Nathalie Thorin-Trescases; Tack-Ki Leung; Eric Thorin; Stanley Nattel
Journal:  Cardiovasc Res       Date:  2003-11-01       Impact factor: 10.787

10.  Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease.

Authors:  Andreas Boldt; Ulrike Wetzel; Josef Weigl; Jens Garbade; Jörg Lauschke; Gerhard Hindricks; Hans Kottkamp; Jan Fritz Gummert; Stefan Dhein
Journal:  J Am Coll Cardiol       Date:  2003-11-19       Impact factor: 24.094

View more
  17 in total

Review 1.  Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation.

Authors:  Fahad Shaikh; Lachlan B Pasch; Phillip J Newton; Beata V Bajorek; Caleb Ferguson
Journal:  Curr Cardiol Rep       Date:  2018-03-24       Impact factor: 2.931

2.  Relation of Atrial Fibrillation in Acute Myocardial Infarction to In-Hospital Complications and Early Hospital Readmission.

Authors:  Amartya Kundu; Kevin O'Day; Amir Y Shaikh; Darleen M Lessard; Jane S Saczynski; Jorge Yarzebski; Chad E Darling; Ramses Thabet; Mohammed W Akhter; Kevin C Floyd; Robert J Goldberg; David D McManus
Journal:  Am J Cardiol       Date:  2016-01-28       Impact factor: 2.778

3.  Severity of Hypertension Correlates with Risk of Thromboembolic Stroke.

Authors:  Hui Pang; Bing Han; Qiang Fu; Qiumei Cao
Journal:  J Cardiovasc Transl Res       Date:  2017-05-31       Impact factor: 4.132

4.  Modifiable Risk Factors and Atrial Fibrillation: the Quest for a Personalized Approach.

Authors:  Lavinia-Lucia Matei; Calin Siliste; Dragos Vinereanu
Journal:  Maedica (Bucur)       Date:  2021-03

5.  Atrial fibrillation in Mexican population: Differences in presentation, comorbidities and risk factors between men and women

Authors:  Humberto Rodríguez-Reyes; César I Laguna-Muñoz; Carlos F Gallegos-de Luna; Manuel O de-Los-Ríos-Ibarra; José L Salas-Pacheco; José L Leyva-Pons; Luz M Muñoz-Gutiérrez; Arturo Vargas-Hernandez; Karla M Rodríguez-Muñoz; Jaime Barragán-Luna; Marco A Alcocer-Gamba; Jorge Cortez-Lawrenz; Julio Farjat-Ruiz
Journal:  Arch Cardiol Mex       Date:  2022-07-01

6.  miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1/STAT3 pathway.

Authors:  Wei Cao; Peng Shi; Jian-Jun Ge
Journal:  BMC Cardiovasc Disord       Date:  2017-03-23       Impact factor: 2.298

Review 7.  American Heart Association High Blood Pressure Protocol 2017: A Literature Review.

Authors:  Asad Ali; Muhammad Abu Zar; Ahmad Kamal; Amber E Faquih; Chandur Bhan; Waleed Iftikhar; Muhammad Bilal Malik; Malik Qistas Ahmad; Nouman Safdar Ali; Shahzad Ahmed Sami; Fnu Jitidhar; Abbas M Cheema; Annum Zulfiqar
Journal:  Cureus       Date:  2018-08-29

8.  Association and impact of hypertension defined using the 2017 AHA/ACC guidelines on the risk of atrial fibrillation in The Atherosclerosis Risk in Communities study.

Authors:  Anas Rattani; J'Neka S Claxton; Mohammed K Ali; Lin Y Chen; Elsayed Z Soliman; Alonso Alvaro
Journal:  BMC Cardiovasc Disord       Date:  2019-11-26       Impact factor: 2.298

9.  Long-term blood pressure trajectories and incident atrial fibrillation in women and men: the Tromsø Study.

Authors:  Ekaterina Sharashova; Tom Wilsgaard; Jocasta Ball; Bente Morseth; Eva Gerdts; Laila A Hopstock; Ellisiv B Mathiesen; Henrik Schirmer; Maja-Lisa Løchen
Journal:  Eur Heart J       Date:  2020-04-21       Impact factor: 29.983

10.  Multimorbidity, physical frailty, and self-rated health in older patients with atrial fibrillation.

Authors:  Hawa O Abu; Jane Saczynski; Jordy Mehawej; Tenes Paul; Hamza Awad; Benita A Bamgbade; Isabelle C Pierre-Louis; Mayra Tisminetzky; Catarina I Kiefe; Robert J Goldberg; David D McManus
Journal:  BMC Geriatr       Date:  2020-09-11       Impact factor: 4.070

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.